JUPITER NEUROSCIENCES, INC.
JUNS evidence brief
What we can confirm
- BioSniper Score:
- 3.8 / 10
- Market Cap:
- $4.0M
- Lead Asset:
- jotrol (Phase 2)
What it means
What to watch
Prepared research question
What matters most for JUNS—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · JUNS
Jupiter Neurosciences, Inc. (JUNS) is a clinical-stage pharmaceutical company developing a patented resveratrol-based platform (JOTROL™) for CNS disorders and rare diseases, while also commercializing a consumer longevity product line (Nugevia™).
Key risk: No revenue, negative equity
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Market Cap
$4.0M
Cash Runway
—
Lead Asset
jotrol (Phase 2)
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 1 pipeline candidate for JUPITER NEUROSCIENCES, INC..
Jupiter Neurosciences, Inc. (JUNS) is a clinical-stage pharmaceutical company developing a patented resveratrol-based platform (JOTROL™) for CNS disorders and rare diseases, while also commercializing a consumer longevity product line (Nugevia™).
- Clinical-stage R&D company focused on CNS disorders and rare diseases, powered by JOTROL™, a proprietary enhanced-resveratrol formulation [sec_mda · as of 2026-08-14].
- Launched Nugevia™ consumer brand in Q4 2025 with three products (GLO, MND, PWR) sold direct-to-consumer [sec_mda · as of 2026-05-14].
- Reported total revenue of $0.0M and net income of -$2.3M for the period ended June 30, 2026 [sec].
- Shareholders' equity was -$0.4M as of June 30, 2026 [sec].
- Entered a term sheet with PharmAla Biotech to license exclusive U.S. rights to ALA-002, a next-generation MDMA therapeutic, in a transaction valued at over $100M [news · published 2026-05-20].
What works
- JOTROL™ platform has demonstrated potential for improved bioavailability compared to standard resveratrol, underpinning both therapeutic and consumer product pipelines [sec_mda · as of 2026-04-01].
- Company has advanced JOTROL™ into a planned Phase IIa clinical study in Parkinson's disease, indicating progress in its therapeutic pipeline [sec_mda · as of 2026-04-01].
- Nugevia™ consumer brand launched in Q4 2025 provides an early revenue channel and brand presence in the longevity market [sec_mda · as of 2026-05-14].
- Secured a term sheet for a potentially high-value licensing deal (over $100M) for ALA-002, expanding pipeline beyond resveratrol [news · published 2026-05-20].
What to weigh
- Company has no revenue from product sales as of June 30, 2026, and reported a net loss of -$2.3M [sec].
- Shareholders' equity is negative (-$0.4M as of June 30, 2026), indicating liabilities exceed assets [sec].
- Company acknowledges historical recurring losses and negative cash flows from operations, and anticipates needing substantial additional capital [sec_mda · as of 2026-05-14].
- Failure to raise capital as needed could negatively impact financial condition and ability to pursue business strategies [sec_mda · as of 2026-08-14].
From the filings
Quoted directly from source documents.
Jupiter Neurosciences is a clinical-stage R&D pharmaceutical company targeting CNS disorders and rare diseases.
“Jupiter Neurosciences, Inc. is a clinical stage research and development pharmaceutical company located in Jupiter, Florida. The Company is advancing a therapeutic pipeline targeting central nervous system ("CNS") dis”
SEC MD&A · August 14, 2026
Nugevia consumer products launched in Q4 2025 via direct-to-consumer model.
“The first products under the Nugevia brand, focusing on supporting longevity and health span are available for sale and shipments began in the fourth quarter of 2025 through a direct-to-consumer model.”
SEC MD&A · May 14, 2026
Company entered a term sheet to license ALA-002 rights for over $100M.
“PharmAla Biotech Signs Term Sheet to License Exclusive U.S. Rights to ALA-002, Its Next-Generation MDMA Therapeutic, to Jupiter Neurosciences, Inc. (NASDAQ: JUNS) in a Transaction Valued at Over $100”
News · May 20, 2026
Risks & what to watch (3)›
Key risks
- No revenue, negative equity — Zero revenue and negative shareholders' equity (-$0.4M) as of June 30, 2026 [sec].
- Dependence on capital raises — Company needs substantial additional capital and has historical losses and negative cash flow [sec_mda · as of 2026-05-14].
- Clinical-stage uncertainty — Pipeline is in early clinical stages (Phase 2a planned for Parkinson's) with no approved therapeutics [sec_mda · as of 2026-04-01].
What to watch
- Progress of the planned Phase IIa clinical study in Parkinson's disease using JOTROL™ [sec_mda · as of 2026-04-01].
- Revenue generation and market adoption of Nugevia™ consumer products [sec_mda · as of 2026-05-14].
- Finalization and execution of the ALA-002 licensing agreement with PharmAla Biotech [news · published 2026-05-20].
- Company's ability to raise additional capital to fund operations and development [sec_mda · as of 2026-08-14].
Sources: News · Pipeline · SEC MD&A · Generated October 2, 2026 · How we verify sources →
Run JUPITER NEUROSCIENCES, INC. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available JUPITER NEUROSCIENCES, INC. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 3 of 6 signals · derived from public data
Cash runway data unavailable
Net income -$2M
Lead: Phase 2
1 candidate
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
10
Total value held
$347K
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 359,911 | $135K |
| geode capital management, llc | 211,696 | $80K |
| yorkville advisors global, lp | 129,000 | $49K |
| citadel advisors llc | 101,661 | $38K |
| vanguard fiduciary trust co | 87,789 | $33K |
| northern trust corp | 25,346 | $10K |
| ubs group ag | 3,928 | $1K |
| midfirst bank | 1,000 | $376 |
| vestor capital, llc | 970,985 | $365 |
| virtu financial llc | 13,575 | $5 |
Short Interest
as of Apr 21, 2026- % of float
- 0.6%
- Days to cover
- 0.7
- Shares short
- 126,917
- Daily short volume (May 8, 2026)
- 28.1%
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
JUNS short interestGovernance
Frequently asked questions
What is the AI investment thesis for JUPITER NEUROSCIENCES, INC.?
Jupiter Neurosciences, Inc. (JUNS) is a clinical-stage pharmaceutical company developing a patented resveratrol-based platform (JOTROL™) for CNS disorders and rare diseases, while also commercializing a consumer longevity product line (Nugevia™).
What is JUPITER NEUROSCIENCES, INC.'s lead drug candidate?
JUPITER NEUROSCIENCES, INC.'s most advanced tracked candidate is jotrol (Phase 2) for Friedreich's ataxia.
Who is the CEO of JUPITER NEUROSCIENCES, INC.?
Mr. Christer Rosen is the chief executive officer of JUPITER NEUROSCIENCES, INC. (JUNS).
Where is JUPITER NEUROSCIENCES, INC. headquartered?
JUPITER NEUROSCIENCES, INC. (JUNS) is headquartered in Jupiter, FL, United States.
What therapeutic areas does JUPITER NEUROSCIENCES, INC. focus on?
JUPITER NEUROSCIENCES, INC. develops therapies across Rare Disease, Neurology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.